|Bid||6.19 x 200|
|Ask||6.50 x 100|
|Day's Range||6.20 - 6.68|
|52 Week Range||1.13 - 9.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 12, 2018 - Mar 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.00|
NEW YORK, Feb. 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Discovery ...
RADNOR, Pa., Feb. 07, 2018-- Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced ...
Marinus Pharmaceuticals (MRNS) has initiated a phase two study to test the feasibility of ganaxalone in patients suffering from refractory status epilepticus (or RSE). Data from this study is expected ...
Marinus Pharmaceuticals (MRNS) announced phase two results from its open-label study evaluating the efficacy of ganaxalone in patients suffering from CDKL5 deficiency disorder (or CDD) in September 2017....
Bain Capital unit Bain Capital Life Sciences Investors LLC owns just two names through subsidiaries, Marinus Pharmaceuticals (MRNS) and Dicerna Pharmaceuticals (DRNA). Over the last several days, Bain has cut back on Marinus and bought more shares of Dicerna. From Dec. 15 through 19 Bain sold nearly 1.3 million shares for $10 million, an average of $7.88 each.
NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, ...
RADNOR, Pa., Dec. 13, 2017-- Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced ...
Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) closed up 39.6 percent Thursday and continued another 3.9 percent pre-market Friday — but not on its own merits. The stock moved mostly on sympathy for SAGE ...
NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Shares of Marinus Pharmaceuticals closed up 14% higher on Thursday after SAGE Therapeutics revealed positive clinical trial data for a postpartum depression ...
Success for Sage Therapeutics' postpartum depression drug bodes well for a related candidate from Marinus Pharmaceuticals.
Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.